Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed renal cell carcinoma (RCC)
• * Clear cell or papillary RCC
• * Granular tumors with sarcomatoid features
• * No purely sarcomatoid RCC, chromophobic RCC, or oncocytoma
• * No transitional cell carcinoma of the renal pelvis and collecting systems
• Metastatic or unresectable disease
• At least 1 measurable lesion
• * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• * The following are not considered measurable:
• * Bone lesions
• * Leptomeningeal disease
• * Ascites
• * Pleural/pericardial effusion
• * Lymphangitis cutis/pulmonis
• * Abdominal masses that are not confirmed and followed by imaging techniques
• * Cystic lesions
• * Primary bladder masses
• Progressive disease after interferon alfa and/or interleukin-2 for metastatic RCC OR intolerance to these therapies
• No prior or concurrent CNS metastases
• * Negative MRI of the brain within the past 28 days
• Must have HLA-identical (6/6) sibling donor
• PATIENT CHARACTERISTICS:
• Age:
• 60 and under
• Performance status:
• ECOG 0-1
• Life expectancy:
• More than 6 months
• Hematopoietic:
• Granulocyte count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 2 times upper limit of normal (ULN)
• AST no greater than 3 times ULN
• Renal:
• Creatinine clearance at least 40 mL/min
• Cardiovascular:
• LVEF at least 45% by MUGA or echocardiogram
• Pulmonary:
• DLCO greater than 40% of predicted (corrected for hemoglobin level)
• No symptomatic pulmonary disease
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No known hypersensitivity to E. coli-derived products
• No uncontrolled diabetes mellitus
• No active serious infection
• No other concurrent malignancy except non-melanoma skin cancer or other malignancy that has less than a 30% risk of relapse after completion of therapy
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• No concurrent sargramostim (GM-CSF)
• Concurrent epoetin alfa allowed
• Chemotherapy:
• No other concurrent chemotherapy
• Endocrine therapy:
• At least 28 days since prior hormonal therapy (e.g., megestrol, corticosteroids, or anti-estrogen therapy)
• Concurrent steroids allowed for adrenal failure, graft-versus-host disease, or other nondisease-related conditions (e.g., insulin for diabetes)
• Radiotherapy:
• At least 14 days since prior radiotherapy
• Surgery:
• At least 14 days since prior surgery
• Other:
• At least 28 days since prior systemic therapy for RCC
• Recovered from prior therapy